Valeant Shakes Confidence Again in Bid to Do Opposite
- Shares down 15% after new CEO tries to explain lower sales
- Valeant files 10-Q report, avoiding nearest risk of default
Valeant Falls After Cutting Profit Forecast
This article is for subscribers only.
What’s the deal with Valeant Pharmaceuticals International Inc. and conference calls?
After just a month on the job, Chief Executive Officer Joe Papa tried to explain to analysts on Tuesday why sales numbers were so dismal for some key drug categories and why he didn’t expect them to get much better this year.